ATRC 37.03 ▲ 4.63% Live Trading Data - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    AtriCure Inc.

    NASDAQ: ATRC · Real-Time Price · USD
    37.03
    1.64 (4.63%)
    At close: Oct 15, 2025, 3:59 PM
    37.03
    0.00%
    After-hours: Oct 15, 2025, 04:10 PM EDT
    4.63%
    Bid 35.44
    Market Cap 1.84B
    Revenue (ttm) 499.95M
    Net Income (ttm) -36.36M
    EPS (ttm) -0.77
    PE Ratio (ttm) -48.09
    Forward PE -161.82
    Analyst Buy
    Dividends n/a
    Ask 37.3
    Volume 481,970
    Avg. Volume (20D) 501,956
    Open 35.64
    Previous Close 35.39
    Day's Range 35.64 - 37.28
    52-Week Range 27.64 - 43.11
    Beta 1.59
    Ex-Dividend Date n/a

    About ATRC

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol ATRC
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for ATRC stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Next Earnings Release

    AtriCure Inc. is scheduled to release its earnings on Oct 29, 2025, after market closes.
    Analysts project revenue of ... Unlock content with Pro Subscription
    2 months ago
    +10.72%
    AtriCure shares are trading higher after the compa... Unlock content with Pro Subscription
    2 months ago
    -4.49%
    AtriCure shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY25 guidance above estimates.
    news image

    1 week ago · businesswire.com

    AtriCure to Announce Third Quarter 2025 Financial Results

    MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-o...

    news image

    1 month ago · businesswire.com

    AtriCure to Participate in the 2025 Wells Fargo Healthcare Conference

    MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-o...

    news image

    2 months ago · fool.com

    AtriCure (ATRC) Q2 Revenue Jumps 17%

    AtriCure (ATRC) Q2 Revenue Jumps 17%

    news image

    2 months ago · seekingalpha.com

    AtriCure, Inc. (ATRC) Q2 2025 Earnings Call Transcript

    AtriCure, Inc. (NASDAQ:ATRC ) Q2 2025 Earnings Conference Call July 29, 2025 4:30 PM ET Company Participants Angela L. Wirick - Chief Financial Officer Michael H.

    news image

    2 months ago · zacks.com

    AtriCure (ATRC) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

    Although the revenue and EPS for AtriCure (ATRC) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street ...

    news image

    2 months ago · zacks.com

    AtriCure (ATRC) Reports Q2 Loss, Tops Revenue Estimates

    AtriCure (ATRC) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to a loss of $0.17 per share a year ago.

    news image

    2 months ago · businesswire.com

    AtriCure Reports Second Quarter 2025 Financial Results; Raises Financial Outlook for 2025

    MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-op...

    news image

    2 months ago · businesswire.com

    AtriCure to Participate in the Canaccord Genuity 45th Annual Growth Conference

    MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-o...

    news image

    3 months ago · businesswire.com

    AtriCure Completes Enrollment in LeAAPS Clinical Trial for Stroke Prevention

    MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain ...

    Add to Watchlist